Mathes Company’s Immix Biopharma IMMX Stock Holding History

Mathes Company’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$97K	Hold	10,650	–	–	0.04%	126
2025 Q4	$56K	Buy	+10,650	New	+$43.8K	0.02%	126

Other funds holding IMMX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Mathes Company's IMMX Position: Q1 2026 in Review

Mathes Company held its Immix Biopharma (IMMX) position steady in Q1 2026 at 10,650 shares worth $97K. The position accounts for 0.04% of the portfolio, ranked #126.

Mathes Company first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

Mathes Company held 10,650 shares of Immix Biopharma worth $97K as of Q1 2026.
Mathes Company left its Immix Biopharma share count unchanged in Q1 2026.
Immix Biopharma made up 0.04% of Mathes Company's portfolio in Q1 2026, its #126 holding.
Mathes Company first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Mathes Company's 13F filing for Q1 2026, filed 8 May 2026.